EGPI FIRECREEK INCORPORATED (OTCBB: EFIR) "Up 100.00% on Monday"
EGPI Firecreek, Inc.'s business and acquisition strategy is focused on producing oil and gas. The Company puts emphasis on acquiring existing fields with proven reserves or by the rehabilitation of oilfields with potentially high throughput. Through its wholly owned subsidiary Energy Producers, Inc., it acquires resource properties and inventories. Through its wholly owned subsidiary Chanwest Resources, LLC it operates as an oil and gas service business. EGPI Firecreek, Inc. is also planning to expand into producing energy through alternative energy sources through their recently acquired Arctic Solar Engineering subsidiary.
PLURISTEM THERAPEUTICS INCORPORATED (NASDAQ: PSTI) "Up 14.80% on Monday"
Pluristem is a clinical stage biotechnology company with proprietary technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem’s patented and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases.
BIOSANTE PHARMACEUTICALS INCORPORATED (NASDAQ: BPAX) "Up 20.80% on Monday"
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at www.biosantepharma.com.
About OTCPicks.com
OTCPicks.com, one of the leading penny stock Web sites, presents its daily Stocks to Watch and Midday Market Movers every weekday. In addition to all the latest penny stock news, OTCPicks also offers daily newsletters, unique commentaries and free profiles, alerts and investing tips.
The stocks presented above are available in OTCPicks.com's Free Daily Email Newsletter. For daily stock alerts go to www.otcpicks.com to sign up.
Disclosure: OTCPicks.com is not currently being compensated by any of the companies covered in this release.
